Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Lymphoid 1Breast 1

Conditions

Breast Neoplasms 19Neoplasm Metastasis 9Carcinoma, Non-Small-Cell Lung 5Prostatic Neoplasms 3Colorectal Neoplasms 3Brain Neoplasms 3Recurrence 2Pancreatic Neoplasms 2Neoplasms 2Melanoma 2Lymphoma, Non-Hodgkin 2Lymphoma 2Carcinoma, Renal Cell 2Advanced Cancer 2Unilateral Breast Neoplasms 1Thrombocytosis 1Solid Tumor 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Recurrent Ovarian High Grade Serous Adenocarcinoma 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Osteosarcoma 1Neuroblastoma 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1

Interventions

Cisplatin 14Pemetrexed 11pembrolizumab 6Cyclophosphamide 6Radiotherapy 3Interleukin-2 3Gemcitabine 3sodium thiosulfate 2sargramostim 2defactinib 2aldesleukin 2Surgical Procedures, Operative 2SS1(dsFv)PE38 2Radiation 2Platinum 2Pharmaceutical Preparations 2Paclitaxel 2Nivolumab 2Drug Therapy 2Depsipeptides 2Decitabine 2Celecoxib 2Carboplatin 21,2-diaminocyclohexaneplatinum II citrate 2osimertinib 1incomplete Freund's adjuvant 1entinostat 1cabozantinib 1bemcentinib 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Mesothelioma, Malignant × abemaciclib × Clear all
NCT01655225 2022-04-08

A Study of LY3023414 in Participants With Advanced Cancer

Eli Lilly and Company

Phase 1 Completed
156 enrolled
BreastLymphoidOther solid neoplasmThoracic

Mesothelioma, Malignant, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lymphoma, Lymphoma, Non-Hodgkin, Mesothelioma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡